Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.
Richard M. Lee‐Ying(Alberta Health Services), Edoardo Francini, Elisa Zanardi(Ospedale Policlinico San Martino), Sabrina Rossetti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Mikol Modesti(Università della Svizzera italiana), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Anna Patrikidou(Institut Gustave Roussy), Thiago Martins Oliveira(D’Or Institute for Research and Education), Calogero Saieva(Istituto per lo Studio e la Prevenzione Oncologica), Giuseppe Fornarini(Ospedale Policlinico San Martino), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Loana Bueno Valença(D’Or Institute for Research and Education), Daniele Santini(Policlinico Umberto I), Antonio Russo(University of Palermo), Christopher Sweeney(Harvard University), Giuseppe Fotia(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniel Yick Chin Heng(University of Calgary), Andrea Malgeri(Università Campus Bio-Medico)
Cited by 0
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k